相似文献
1
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.
Emerg Infect Dis. 2021 Jan;27(1):332-4. doi: 10.3201/eid2701.203766. Epub 2020 Nov 23.
2
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
BMJ Open. 2021 Dec 3;11(12):e051521. doi: 10.1136/bmjopen-2021-051521.
3
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
Clin Infect Dis. 2023 Oct 5;77(7):1053-1062. doi: 10.1093/cid/ciad312.
4
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0003523. doi: 10.1128/aac.00035-23. Epub 2023 Mar 15.
5
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
Clin Microbiol Infect. 2024 Sep;30(9):1197.e1-1197.e4. doi: 10.1016/j.cmi.2024.03.009. Epub 2024 Mar 13.
6
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
Int J Tuberc Lung Dis. 2021 Jun 1;25(6):453-460. doi: 10.5588/ijtld.21.0035.
7
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00021-19. Print 2019 May.
8
Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
BMJ Case Rep. 2021 Dec 7;14(12):e245612. doi: 10.1136/bcr-2021-245612.
9
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
Clin Infect Dis. 2024 Mar 20;78(3):730-741. doi: 10.1093/cid/ciad653.
10
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0156223. doi: 10.1128/aac.01562-23. Epub 2024 Feb 20.
引用本文的文献
1
Pisces: A multi-modal data augmentation approach for drug combination synergy prediction.
Cell Genom. 2025 Jul 9;5(7):100892. doi: 10.1016/j.xgen.2025.100892. Epub 2025 Jun 3.
2
Novel six-month all oral treatment of pre-extensively drug-resistant tuberculosis in Canada: New treatment options present new implementation challenges.
Can Commun Dis Rep. 2023 Jan 5;49(1):15-20. doi: 10.14745/ccdr.v49i01a04.
3
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0156223. doi: 10.1128/aac.01562-23. Epub 2024 Feb 20.
4
Molecular determinants of multidrug-resistant tuberculosis in Sierra Leone.
Microbiol Spectr. 2024 Mar 5;12(3):e0240523. doi: 10.1128/spectrum.02405-23. Epub 2024 Jan 30.
5
Application of Chiral Transfer Reagents to Improve Stereoselectivity and Yields in the Synthesis of the Antituberculosis Drug Bedaquiline.
Org Process Res Dev. 2023 Oct 13;27(11):2146-2159. doi: 10.1021/acs.oprd.3c00287. eCollection 2023 Nov 17.
6
Rifampin Mono-Resistant Tuberculosis in New York City, 2010-2021: A Retrospective Case Series.
Open Forum Infect Dis. 2023 Nov 21;10(11):ofad534. doi: 10.1093/ofid/ofad534. eCollection 2023 Nov.
7
Exploring the potential of multi-target-directed ligands for tuberculosis treatment.
Ther Adv Infect Dis. 2023 Jul 15;10:20499361231188039. doi: 10.1177/20499361231188039. eCollection 2023 Jan-Dec.
8
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
Clin Infect Dis. 2023 Oct 5;77(7):1053-1062. doi: 10.1093/cid/ciad312.
9
FLASH-TB: an Application of Next-Generation CRISPR to Detect Drug Resistant Tuberculosis from Direct Sputum.
J Clin Microbiol. 2023 Apr 20;61(4):e0163422. doi: 10.1128/jcm.01634-22. Epub 2023 Apr 3.
10
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0003523. doi: 10.1128/aac.00035-23. Epub 2023 Mar 15.
本文引用的文献
1
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
N Engl J Med. 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814.
2
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST.
3
WHO global progress report on tuberculosis elimination.
Lancet Respir Med. 2020 Jan;8(1):19. doi: 10.1016/S2213-2600(19)30418-7. Epub 2019 Nov 6.
4
Pretomanid: First Approval.
Drugs. 2019 Nov;79(16):1797-1803. doi: 10.1007/s40265-019-01207-9.
5
Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.
Int J Antimicrob Agents. 2019 Mar;53(3):275-283. doi: 10.1016/j.ijantimicag.2018.10.012. Epub 2018 Oct 29.
6
Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00239-17. Print 2017 Jun.
7
The Role of Therapeutic Drug Monitoring in Mycobacterial Infections.
Microbiol Spectr. 2017 Jan;5(1). doi: 10.1128/microbiolspec.TNMI7-0029-2016.
8
Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis.
EBioMedicine. 2015 Oct 9;2(11):1627-33. doi: 10.1016/j.ebiom.2015.09.051. eCollection 2015 Nov.
9
Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
mBio. 2015 Nov 3;6(6):e01741-15. doi: 10.1128/mBio.01741-15.
10
Linezolid for treatment of chronic extensively drug-resistant tuberculosis.
N Engl J Med. 2012 Oct 18;367(16):1508-18. doi: 10.1056/NEJMoa1201964.
Zotero 插件